Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx

Background<p>The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of fi...

保存先:

書誌詳細
第一著者:	Xiaohu Jin (9618675) (author)
その他の著者:	Zhifeng Li (1776799) (author)
出版事項:	2025
主題:	Pharmacology cost-effectiveness analysis CDK4/6 inhibitors endocrine therapy HR+/HER2- breast cancer SONIA
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary file 2_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
著者:: Xiaohu Jin (9618675)
出版事項: (2025)

Data Sheet 1_Anti-HER2/neu TCR-T Cells in Action: linking transcriptional signatures, secretomics, and In Vivo tumor suppression.docx
著者:: Saleh Alrhmoun (19193851)
出版事項: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
著者:: Kazuhito Suzuki (22688384)
出版事項: (2025)

Line plots of performance metrics across TFIDF conditions.
著者:: Stefan Saverimuttu (20882325)
出版事項: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
著者:: Gregory L. Beatty (15087193)
出版事項: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
著者:: Gregory L. Beatty (15087193)
出版事項: (2025)

The time-course of information alignment, split by first and second experiment half.
著者:: Denise Moerel (9080849)
出版事項: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
著者:: Andrew A. Davis (15030032)
出版事項: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
著者:: Xinhang Gu (22686224)
出版事項: (2025)

Probability of second result being 10 mg/L different than first result.
著者:: Alex Gough (16734033)
出版事項: (2025)

The contribution of shared rules to neural information alignment, for the first (A) and second (B) experiment half.
著者:: Denise Moerel (9080849)
出版事項: (2025)

Scatter and line plots of cluster number and mean cluster size as wgs percentage in mixture increases, subset dataset.
著者:: August Guang (9975678)
出版事項: (2025)

Scatter and line plots of cluster number and mean cluster size as wgs percentage in mixture increases, full dataset.
著者:: August Guang (9975678)
出版事項: (2025)

Comparison of Severity Grade and Normal EMG Between First and Second EMG Assessments in dialysis group at T2.
著者:: Arwa Yahyaoui (22683276)
出版事項: (2025)

Table 2_Effect of preoperative intranasal dexmedetomidine versus placebo on intraoperative shivering in parturients undergoing cesarean section: a randomized controlled trial.docx
著者:: Guolin Xu (2963358)
出版事項: (2025)

Table 1_Effect of preoperative intranasal dexmedetomidine versus placebo on intraoperative shivering in parturients undergoing cesarean section: a randomized controlled trial.docx
著者:: Guolin Xu (2963358)
出版事項: (2025)

Computational cost of the analyses.
著者:: Raúl López-Martín (21386066)
出版事項: (2025)

Electrophysiological development and functional plasticity in dissociated human cerebral organoids across multiple cell lines - Raw MEA data (2 of 4)
著者:: Adam Pavlinek (20917388)
出版事項: (2025)

Electrophysiological development and functional plasticity in dissociated human cerebral organoids across multiple cell lines - Well average data and metadata (1 of 4)
著者:: Adam Pavlinek (20917388)
出版事項: (2025)

Data Sheet 1_MicroRNA identification and expression analysis of wheat thermo-sensitive male sterile line BNS366 for fertility transformation.zip
著者:: Junpeng Chen (4927267)
出版事項: (2025)

Supplemental Figure 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Figure 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Table 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Table 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Table 3 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Table 4 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Supplementary Table 5 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
著者:: William C. Reinhold (16015934)
出版事項: (2025)

Evolution of EMG parameters between first and second EMG among children having an End Stage Kidney Disease with an Uremic neuropathy (n = 24).
著者:: Arwa Yahyaoui (22683276)
出版事項: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
著者:: Takeru Oka (15386810)
出版事項: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
著者:: Takeru Oka (15386810)
出版事項: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_j7du7mcrvog5sperakm7rrsa2b